Nothing Special   »   [go: up one dir, main page]

ATE147074T1 - Verbindungen welche antihypertensive und antiischemische eigenschaften besitzen - Google Patents

Verbindungen welche antihypertensive und antiischemische eigenschaften besitzen

Info

Publication number
ATE147074T1
ATE147074T1 AT91917927T AT91917927T ATE147074T1 AT E147074 T1 ATE147074 T1 AT E147074T1 AT 91917927 T AT91917927 T AT 91917927T AT 91917927 T AT91917927 T AT 91917927T AT E147074 T1 ATE147074 T1 AT E147074T1
Authority
AT
Austria
Prior art keywords
compounds
possess
possess antihypertensive
antiischemic
properties
Prior art date
Application number
AT91917927T
Other languages
English (en)
Inventor
Alfred P Spada
Cynthia A Fink
Michael R Myers
Original Assignee
Rhone Poulenc Rorer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Int filed Critical Rhone Poulenc Rorer Int
Application granted granted Critical
Publication of ATE147074T1 publication Critical patent/ATE147074T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT91917927T 1990-09-25 1991-09-25 Verbindungen welche antihypertensive und antiischemische eigenschaften besitzen ATE147074T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58788490A 1990-09-25 1990-09-25

Publications (1)

Publication Number Publication Date
ATE147074T1 true ATE147074T1 (de) 1997-01-15

Family

ID=24351576

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91917927T ATE147074T1 (de) 1990-09-25 1991-09-25 Verbindungen welche antihypertensive und antiischemische eigenschaften besitzen

Country Status (14)

Country Link
US (1) US5364862A (de)
EP (1) EP0550631B1 (de)
JP (1) JP2505085B2 (de)
AT (1) ATE147074T1 (de)
AU (1) AU654507B2 (de)
CA (1) CA2092305C (de)
DE (1) DE69123974T2 (de)
DK (1) DK0550631T3 (de)
ES (1) ES2095960T3 (de)
GR (1) GR3022207T3 (de)
HK (1) HK1002031A1 (de)
MX (1) MX9203771A (de)
SG (1) SG80526A1 (de)
WO (1) WO1992005177A1 (de)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679650A (en) * 1993-11-24 1997-10-21 Fukunaga; Atsuo F. Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
ATE147074T1 (de) * 1990-09-25 1997-01-15 Rhone Poulenc Rorer Int Verbindungen welche antihypertensive und antiischemische eigenschaften besitzen
FR2685918B1 (fr) * 1992-01-08 1995-06-23 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
US5705491A (en) * 1992-10-27 1998-01-06 Nippon Zoki Pharmaceutical Co., Ltd. Adenosine deaminase inhibitor
DK155292D0 (da) * 1992-12-23 1992-12-23 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
US5683989A (en) * 1993-12-17 1997-11-04 Novo Nordisk A/S Treatment of ischemias by administration of 2,N6 -substituted adenosines
FR2714907B1 (fr) * 1994-01-07 1996-03-29 Union Pharma Scient Appl Nouveaux dérivés de l'Adénosine, leurs procédés de préparation, compositions pharmaceutiques les contenant.
WO1995018817A1 (fr) * 1994-01-07 1995-07-13 Laboratoires Upsa Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant
GB9414208D0 (en) * 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
US5670649A (en) * 1995-05-30 1997-09-23 Rhone-Poulenc Rorer S.A. Derivatives of 2-azabicyclo 2.2.1!heptane, their preparation and their application
US5684159A (en) * 1995-05-30 1997-11-04 Rhone-Poulenc Rorer S.A. L-tartaric acid salt of a (1R) diastereomer of a 2-azadihydroxybicyclo 2.2.1!heptane compound and the preparation of 2-azabicyclo 2.2.1!heptane compounds
FR2734822B1 (fr) * 1995-05-30 1997-07-04 Rhone Poulenc Rorer Sa Nouveaux derives du 2-azabicyclo(2.2.1)heptane, leur preparation et leur application
ZA9756B (en) * 1996-01-16 1997-07-17 Warner Lambert Co Process for preparing 4,6-disubstituted pyrido[3,4-d]-pyrimidines
US6376472B1 (en) 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
UA51716C2 (uk) * 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
US5747474A (en) * 1996-07-29 1998-05-05 Immune Modulation, Inc. Immunosuppression by administration of N6,N6 -disubstituted cAMP's, analogues thereof, and related nucleosides
CN1112354C (zh) * 1996-09-12 2003-06-25 阿温蒂斯药物公司 手性1－芳基－和1－杂芳基－2－取代的乙基－2－胺的立体选择性制备
ES2242984T3 (es) * 1996-12-11 2005-11-16 Aventis Pharmaceuticals Inc. Preparacion de (1s-(1a,2b,3b,4a(s*)))-4-(7-((1-(3-cloro-2-tienil) metil)propil)amino)-3h-imidazo (4,5-b)piridin-3-il)-n-etil-2-3-dihidroxiciclopentancarboxamida.
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
US6440947B1 (en) 1997-10-07 2002-08-27 The Regents Of The University Of California Method for treating occlusive peripheral vascular disease and coronary disease
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
PL345062A1 (en) 1998-06-23 2001-11-19 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
JP3619017B2 (ja) 1998-06-24 2005-02-09 日本臓器製薬株式会社 新規アラビノシルアデニン誘導体
IL143843A0 (en) * 1998-12-21 2002-04-21 Aventis Pharm Prod Inc Process for preparing n6-substituted deaza-adenosine derivatives
EP1140933B1 (de) 1998-12-31 2004-09-08 Aventis Pharmaceuticals Inc. Verfahren zur herstellung von n6-substituierten deaza-adenosinderivaten
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6784165B1 (en) * 1999-11-23 2004-08-31 Aderis Pharmaceuticals, Inc. Treatment of heart rhythm disturbances with N6-substituted-5′-(N-substituted) carboxamidoadenosines
US20020045613A1 (en) * 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
HU228783B1 (en) * 2001-07-26 2013-05-28 Greenearth Cleaning Dry cleaning apparatus and method capable of utilizing a siloxane solvent
JP4514452B2 (ja) 2001-10-01 2010-07-28 ユニバーシティ オブ バージニア パテント ファウンデーション Ａ２ａアゴニスト活性を有する２−プロピルアデノシン・アナログおよびその組成物
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
US7265111B2 (en) * 2002-06-27 2007-09-04 Sanofi-Aventis Deutschland Gmbh Adenosine analogues and their use as pharmaceutical agents
CA2513545A1 (en) * 2003-01-17 2004-08-05 Ajinomoto Co., Inc. Processes for production of nucleosides
US20050009776A1 (en) * 2003-04-24 2005-01-13 Aderis Pharmaceuticals, Inc. Method of treating atrial fibrillation or atrial flutter
US20050118262A1 (en) * 2003-09-17 2005-06-02 Jack Aurora Controlled release formulation
EP1574508A1 (de) * 2004-01-30 2005-09-14 Lonza AG Verfahren zur Herstellung von Acetalen und Ketalen von 3-Amino-5-(hydroxymethyl)-cyclopentan-1,2-diolen, sowie deren Derivaten und Salzen
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
WO2006028618A1 (en) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
AU2005267706B2 (en) 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
JP2008520744A (ja) 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US8178509B2 (en) 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
PT2004654E (pt) 2006-04-04 2013-08-27 Univ California Derivados de pirazolopirimidina para utilização como antagonistas da quinase
GB0607954D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PE20080361A1 (es) 2006-04-21 2008-06-03 Novartis Ag Compuestos derivados de purina como activadores del receptor de adenosina a2a
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
EP1889846A1 (de) 2006-07-13 2008-02-20 Novartis AG Purinderivate als A2a Agonisten
EP1903044A1 (de) 2006-09-14 2008-03-26 Novartis AG Adenosinderivate als Agonisten des A2A-Rezeptors
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
EP2240451B1 (de) 2008-01-04 2017-08-09 Intellikine, LLC Durch Purin substituierte Isochinolinonderivate zur Verwendung als PI3K-Hemmer
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2252293B1 (de) 2008-03-14 2018-06-27 Intellikine, LLC Kinasehemmer und verwendungsverfahren
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
KR20110039326A (ko) 2008-07-08 2011-04-15 인텔리카인, 인크. 키나제 억제제 및 사용 방법
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
EP2358720B1 (de) 2008-10-16 2016-03-02 The Regents of The University of California Heteroarylkinasehemmer mit kondensierten ringen
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
CA2760791C (en) 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
WO2011146882A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2655362A1 (de) 2010-12-22 2013-10-30 Abbvie Inc. Hepatitis-c-inhibitoren und ihre verwendung
MX347708B (es) 2011-01-10 2017-05-09 Infinity Pharmaceuticals Inc Proceso para preparar isoquinolinonas y formas solidas de isoquinolinonas.
AR085397A1 (es) 2011-02-23 2013-09-25 Intellikine Inc Combinacion de inhibidores de quinasa y sus usos
CA2842190A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
EP2734520B1 (de) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclische verbindungen und ihre verwendung
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6342805B2 (ja) 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
SG11201502331RA (en) 2012-09-26 2015-04-29 Univ California Modulation of ire1
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TWI657085B (zh) 2013-10-04 2019-04-21 英菲尼提製藥股份有限公司 雜環化合物及其用途
EP3060566B1 (de) * 2013-10-23 2018-09-05 Academia Sinica Verbindungen zur verwendung bei der vorbeugung und behandlung neurodegenerativer erkrankungen und schmerzen
MX2016012021A (es) 2014-03-19 2017-04-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2016322552B2 (en) 2015-09-14 2021-03-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
UA125216C2 (uk) 2016-06-24 2022-02-02 Інфініті Фармасьютікалз, Інк. Комбінована терапія
EP3884026B1 (de) 2018-11-20 2024-06-26 Unilever Global Ip Limited Reinigungsmittelzusammensetzung
WO2022135365A1 (en) * 2020-12-22 2022-06-30 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Disubstituted cyclopentane kinase inhibitors
KR102308854B1 (ko) * 2021-02-26 2021-10-05 퓨쳐메디신 주식회사 카보사이클릭 뉴클레오사이드 유도체를 포함하는 코로나바이러스감염증-19 예방 및 치료용 약학적 조성물

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL128629C (de) * 1966-05-07
BE768925A (fr) * 1970-06-30 1971-11-03 Takeda Chemical Industries Ltd Derives d'adenosine et procede de preparation
DE2059922A1 (de) * 1970-12-05 1972-06-15 Boehringer Mannheim Gmbh Neue N(6)-Aralkyl-adenosin-Derivate und Verfahren zur Herstellung derselben
DE2205002A1 (de) * 1972-02-03 1973-08-09 Merck Patent Gmbh Adenosinderivate
DE2136624A1 (de) * 1971-07-22 1973-02-08 Boehringer Mannheim Gmbh N (6)-substituierte adenosin-derivate und verfahren zur herstellung derselben
DE2139107A1 (de) * 1971-08-04 1973-02-15 Merck Patent Gmbh Heterocyclisch substituierte adenosinverbindungen
DE2151013C2 (de) * 1971-10-08 1983-04-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von in N↑6↑-Stellung gegebenenfalls substituierten 6-Amino- und 2,6-Diaminopurinnucleosiden
US3914415A (en) * 1973-06-14 1975-10-21 Abbott Lab Adenosine-5{40 -carboxylic acid amides
US4167565A (en) * 1976-11-08 1979-09-11 Abbott Laboratories Adenosine-5'-carboxamides and method of use
JPS5921928A (ja) * 1982-07-28 1984-02-04 Haruo Kojima 給湯装置
JPS59219284A (ja) * 1983-05-27 1984-12-10 Toyo Jozo Co Ltd ３′−デオキシネプラノシンａおよびその製造法
US4501735A (en) * 1983-12-05 1985-02-26 Warner-Lambert Company N6-(1- and 2-benzocycloalkyl) adenosines
ATE50777T1 (de) * 1984-04-18 1990-03-15 Whitby Research Inc Cardio-vasodilatatore n-6-substituierte adenosine.
US4657897A (en) * 1984-06-22 1987-04-14 Warner-Lambert Company N6 -substituted adenosines for treating pain
US4657898A (en) * 1984-06-22 1987-04-14 Warner-Lambert Company N6 -substituted adenosines and method of use
AU575438B2 (en) * 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
US4593019A (en) * 1984-10-26 1986-06-03 Warner-Lambert Company N6 -tricyclic adenosines
US4663313A (en) * 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
US4683223A (en) * 1985-09-09 1987-07-28 Warner-Lambert Company N6 -Benzopyrano-and benzothiopyrano adenosines and methods of use
US4600707A (en) * 1985-01-25 1986-07-15 Warner-Lambert Company Benzothien-3-yl adenosine; benzothien-3-yl adenosine, S-oxide; and benzothien-3-yl, S,S-dioxide adenosine compounds
US4636493A (en) * 1985-01-25 1987-01-13 Warner-Lambert Company Benzothien-3-yl adenosine; benzothien-3-yl adenosine, S-oxide; and benzothien-3-yl, S,S-dioxide adenosine compounds
DE3529497A1 (de) * 1985-08-17 1987-02-26 Boehringer Mannheim Gmbh N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US4738954A (en) * 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4755594A (en) * 1986-01-31 1988-07-05 Warner-Lambert Company N6 -substituted adenosines
US4780452A (en) * 1986-09-08 1988-10-25 Burroughs Wellcome Co. F-substituted-3-β-D-ribofuranosyl-3H-imidazo[4,5-b]pyridines and pharmaceutical compositions thereof
WO1988003148A2 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Heteroaromatic derivatives of adenoside
WO1988003147A1 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
US5063233A (en) * 1986-11-14 1991-11-05 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives useful as adenosine receptor agonists
US4954504A (en) * 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
US4843066A (en) * 1986-11-27 1989-06-27 Nippon Zoki Pharmaceutical Co., Ltd. Novel adenosine derivatives and pharmaceutical composition containing them as an active ingredient
HU198950B (en) * 1986-12-15 1989-12-28 Sandoz Ag Process for producing new furanuronic acid derivatives and pharmaceutical compositions comprising such compounds
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
PT86660B (pt) * 1987-02-04 1992-02-28 Ciba Geigy Ag Processo para a preparacao de derivados de adenosina-5'-carboxamida
CA1340361C (en) * 1987-04-24 1999-02-02 Whitby Research, Inc. N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists
GB8729994D0 (en) * 1987-12-23 1988-02-03 Glaxo Group Ltd Chemical compounds
AU3820989A (en) * 1988-08-02 1990-02-08 Ciba-Geigy Ag 7-amino-3-beta-d-ribofuranosyl-3h-imidazo(4,5-b) pyridin-5-amine derivatives
US4977144A (en) * 1988-08-02 1990-12-11 Ciba-Geigy Corporation Imidazo[4,5-b]pyridine derivatives as cardiovascular agents
GB2226027B (en) * 1988-12-13 1992-05-20 Sandoz Ltd Adenosine derivatives,their production and use
JPH0725785B2 (ja) * 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
GB8916480D0 (en) * 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
ATE147074T1 (de) * 1990-09-25 1997-01-15 Rhone Poulenc Rorer Int Verbindungen welche antihypertensive und antiischemische eigenschaften besitzen

Also Published As

Publication number Publication date
DE69123974T2 (de) 1997-05-07
GR3022207T3 (en) 1997-04-30
CA2092305A1 (en) 1992-03-26
EP0550631B1 (de) 1997-01-02
SG80526A1 (en) 2001-05-22
CA2092305C (en) 2003-02-11
US5364862A (en) 1994-11-15
JP2505085B2 (ja) 1996-06-05
JPH05508864A (ja) 1993-12-09
DK0550631T3 (da) 1997-01-20
DE69123974D1 (de) 1997-02-13
EP0550631A4 (en) 1994-08-10
ES2095960T3 (es) 1997-03-01
WO1992005177A1 (en) 1992-04-02
AU654507B2 (en) 1994-11-10
AU8726691A (en) 1992-04-15
MX9203771A (es) 1992-09-01
EP0550631A1 (de) 1993-07-14
HK1002031A1 (en) 1998-07-24

Similar Documents

Publication Publication Date Title
ATE147074T1 (de) Verbindungen welche antihypertensive und antiischemische eigenschaften besitzen
CA2188147A1 (en) Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
CA2259538A1 (en) Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
BG60698B2 (en) Pharmaceutical ACCEPTABLE SALTS
DE69422191D1 (de) A1 adenosin rezeptor agonisten und antagonisten
DE69132141D1 (de) Neuroprotective indolone und verwandte derivate
PT1274687E (pt) Derivados de 1,2,3,4-tetra-hidroisoquinolina
EA200101203A1 (ru) Производные пурина
DE60021282D1 (de) Carbamat-derivate als muscarin-rezeptor antonisten
FR2757521B1 (fr) Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
DE3773737D1 (de) 4,5,6,7-tetrahydro-1h-imidazo(4,5-c)pyridinderivate und analoge mit antihypertensiver wirkung.
RU94031126A (ru) Циклические мочевины и их аналоги, пригодные в качестве ингибиторов протеазы ретровирусов, способ лечения вирусных инфекций, фармацевтическая композиция
HUP0101669A2 (hu) Egy vírusellenes hatású benzimidazol vegyület új kristályos formái
RU93046497A (ru) Фенильные гетероциклические производные, способ их получения, фармацевтическая композиция и промежуточный продукт
MXPA03004779A (es) Nuevas benzazepinas y derivados heterociclicos relacionados, utiles como antagonistas del receptor de orexina.
TNSN99191A1 (fr) Derives d'adenine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MX9203050A (es) Compuestos de analogos de triptamina.
FR2743562B1 (fr) Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant
ES2191659T3 (es) Derivados heterociclicos substituidos utiles como inhibidores de la agregacion plaquetaria.
DK1019426T3 (da) Hidtil ukendte A1-adenosinreceptoragonister og -antagonister
BG101867A (en) Benzothiazenedioxides as endothelin antagonists
ATE213233T1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
DK478485D0 (da) 4-oxo-pyrido(2,3-d)pyrimidin-derivater, deres fremstilling og anvendelse
DE68919280D1 (de) Alpha-adrenergische Rezeptorantagonisten.
RU93046495A (ru) Гетероциклические соединения, промежуточные соединения, способ получения и фармацевтическая композиция

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee